Navigation Links
Smith & Nephew CEO Interviewed on Q2 2011 Results
Date:8/5/2011

LONDON, August 5, 2011 /PRNewswire/ --

 

Medical devices group Smith & Nephew reports sales growth of 12% and underlying sales growth of 5%.

In an interview with financial broadcaster http://www.cantos.com, new CEO Olivier Bohuon talks Q2 results and introduces his plans for a new Strategic Framework that details efficiency plans and announces a new focus on emerging markets. 

Bohuon also announced plans to inject an additional $300m into R&D over the next five years, and to focus the business on performance, innovation and a more global presence.

The interview and transcript are available now on http://www.cantos.com/company/Smith%20and%20Nephew

Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email prnsupport@cantos.com or phone +44-207-936-1352.


'/>"/>
SOURCE Smith & Nephew plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
2. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
3. Canadas Michael Smith Genome Sciences Center Validates NEBNextâ„¢ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing
4. GlaxoSmithKline and Amplimmune Form Global Strategic Collaboration
5. Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee
6. Academics Launch New Web Site Holding Jeffrey Smith's Claims on GM Foods Up to Peer-Reviewed Science
7. SpineSmith to Present at the 5th Annual Stem Cell Summit
8. SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement
9. ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales
10. FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKlines Candidate Cervical Cancer Vaccine
11. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):